Hernández Isabel, Mauleón Ana, Rosense-Roca Maiteé, Alegret Montserrat, Vinyes Georgina, Espinosa Anna, Sotolongo-Grau Oscar, Becker James T, Valero Sergi, Tarraga Lluís, López Oscar L, Ruiz Agustín, Boada Mercè
Fundacio ACE, Marques de Sentmenat, 57, 08029 Barcelona (Spain).
Curr Alzheimer Res. 2014 Feb;11(2):182-91. doi: 10.2174/1567205010666131212120443.
Postmortem and genetic studies of clinically diagnosed Frontotemporal dementia (FTD) patients suggest that a number of clinically diagnosed FTD patients are actually "frontal variants" of Alzheimer's disease (fvAD). The purpose of this study was to evaluate this hypothesis by combining neuropathological data, genetic association studies of APOE, phenotype-APOE genotype correlations and discriminant analysis techniques.
Neuropathological information on 24 FTD cases, genetic association studies of APOE (168 FTD, 3083 controls and 2528 AD), phenotypegenotype correlations and discriminant techniques (LDA, logistic regression and decision trees) were combined to identify fvAD patients within a clinical FTD series.
Four of 24 FTLD patients (16.6%) met criteria for definite AD. By comparing allele and genotype frequencies of APOE in controls, FTD and AD groups and by applying the Hardy- Weinberg equilibrium law (HWE), we inferred a consistent (17.2%) degree of AD contamination in clinical FTD. A penetrance analysis for APOE ε4 genotype in the FTD series identified 14 features for discrimination analysis. These features were compared between clinical AD (n=332) and clinical FTD series (n=168) and classifiers were constructed usinglinear discriminant analysis logistic regression or decision tree techniques. The classifier had 92.8% sensitivity to FTD and 93.4% sensitivity to AD relative to neuropathology (global AUC=0.939, p<<0.001). We identified 30 potential fvAD cases (17.85%) in the clinical FTD sample.
The APOE locus association in clinical FTD might be entirely explained by the existence of "hidden" fvAD cases within an FTD sample. The degree of fvAD contamination can be inferred from APOE genotypes.
对临床诊断为额颞叶痴呆(FTD)患者的尸检和基因研究表明,许多临床诊断为FTD的患者实际上是阿尔茨海默病的“额叶变异型”(fvAD)。本研究的目的是通过结合神经病理学数据、APOE基因关联研究、表型-APOE基因型相关性以及判别分析技术来评估这一假设。
将24例FTD病例的神经病理学信息、APOE基因关联研究(168例FTD、3083例对照和2528例AD)、表型-基因型相关性以及判别技术(线性判别分析、逻辑回归和决策树)相结合,以在临床FTD系列中识别fvAD患者。
24例FTLD患者中有4例(16.6%)符合确诊AD的标准。通过比较对照组、FTD组和AD组中APOE的等位基因和基因型频率,并应用哈迪-温伯格平衡定律(HWE),我们推断临床FTD中存在一致的(17.2%)AD污染程度。对FTD系列中APOE ε4基因型的外显率分析确定了14个用于判别分析的特征。将这些特征在临床AD(n = 332)和临床FTD系列(n = 168)之间进行比较,并使用线性判别分析、逻辑回归或决策树技术构建分类器。相对于神经病理学,该分类器对FTD的敏感性为92.8%,对AD的敏感性为93.4%(全局AUC = 0.939,p << 0.001)。我们在临床FTD样本中识别出30例潜在的fvAD病例(17.85%)。
临床FTD中APOE基因座关联可能完全由FTD样本中“隐藏”的fvAD病例的存在来解释。fvAD污染程度可从APOE基因型推断得出。